California-based biotech Cytokinetcs (NASDAQ: CYTK) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in...
Sanofi will acquire exclusive rights to aficamten for treating hypertrophic cardiomyopathy in Greater China from Corxel Pharmaceuticals.Quiver AI SummaryCytokinetics, Inc. announced that Sanofi will acquire...
Fady Ibraham Malik, the EVP Research & Development of $CYTK ($CYTK), sold 5,300 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...
Cytokinetics, Incorporated CYTK announced that the late-stage COMET-HF study on pipeline candidate, omecamtiv mecarbil, has started.COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart...
Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate, aficamten.Aficamten is a next-in-class cardiac myosin inhibitor....
Robert I Blum, the President & CEO of $CYTK ($CYTK), sold 5,000 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.2% of their...
FDA sets September 26, 2025, action date for Cytokinetics' aficamten treatment application for obstructive hypertrophic cardiomyopathy.Quiver AI SummaryCytokinetics, Inc. announced that the FDA has accepted...